Inspire Medical Stock Surges Over 27% on Surprise Q2 Profit and Raised Outlook

Shares of Inspire Medical Systems (NYSE: INSP) surged more than 27% in recent trading after the medical technology company reported second-quarter financial results that significantly surpassed Wall Street expectations, including a surprise profit.

Blowout Quarterly Results

Inspire Medical, which develops minimally invasive treatments for sleep apnea, announced a strong performance that defied analyst forecasts. The company posted an adjusted earnings per share (EPS) of $0.14, a stark contrast to the consensus estimate of a $0.24 loss per share.

Key financial highlights from the second-quarter report include:

• Revenue: $200.6 million.
• Adjusted EPS: $0.14, representing a positive surprise of over 158% compared to loss expectations.
• Adjusted EBITDA: Surpassed forecasts by 40%.

The company attributed the strong performance to several factors, including accelerating adoption in Europe, improvements in prior-authorization workflows, and clearer reimbursement coding for its devices.

Upgraded Forecast and Strategic Plan

Ad

Buoyed by the strong quarterly momentum, Inspire Medical's management raised its full-year 2026 revenue guidance to a range of $835 million to $875 million. The company also announced a new strategic initiative, dubbed "Project Horizon."

This restructuring plan is designed to unlock approximately $30 million in growth capital. The company stated these funds will be reinvested directly into market expansion efforts, signaling confidence in its continued growth trajectory.

Market Context

The significant stock rally reflects investor optimism following a period where the stock had been trading well below its 52-week high. The latest earnings report appears to validate the company's underlying fundamentals, which include high gross margins of around 85% and a dominant position in a market estimated to be worth over $10 billion.

Regulatory tailwinds, such as a previous update to a key CMS reimbursement code, have also provided greater clarity and access for its Inspire V device, further solidifying its competitive position against traditional treatment alternatives.